The current study was undertaken to examine the results of femoropopliteal bypass grafting with intermittent claudication as the indication. Of 1173 infrainguinal reconstructions carried out on our service during the past decade, 249 (21%) consecutive femoropopliteal grafts were performed for disabling claudication in 191 patients. The primary five-year cumulative patency rates were 78% for autogenous vein and 52% for polytetrafluoroethylene grafts. There were two (0.8%) 30-day operative deaths and a subsequent five-year amputation rate of 2.4% for both groups. Femoropopliteal reconstruction for claudication may therefore be carried out with acceptably low operative mortality and a subsequent amputation rate comparable with that anticipated from the natural history of the disease. While the five-year patency rate is significantly higher utilizing autogenous vein grafts, symptomatic relief may be expected with prosthetic grafts in approximately half the patients without incurring a higher risk of limb loss.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archsurg.1988.01400340022003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Omniflow prosthesis for treatment prosthetic graft infection of the aorto-iliac and femoropopliteal level on the infrarenal aortic segment and lower extremity.
Ann Vasc Surg
January 2025
Department of for Cardiovascular Surgery, University Heart Centre Freiburg - Bad Krozingen, University Medical Centre Freiburg, Freiburg, Germany; Faculty of Medicine, Albert Ludwigs University Freiburg, Freiburg, Germany.
Objectives: To report outcomes after the use of the Omniflow II biosynthetic graft (LeMaitre Vascular, Il, USA) for vascular reconstruction in patients with prosthetic infection at the aorto-iliac and femoropopliteal level.
Methods: Within a six-year period, all consecutive patients with aorto-iliac and femoro-popliteal graft infection treated by resection of the infected graft material, extensive local debridement and reconstruction using Omniflow II biosynthetic graft were retrospectively analzyed. Patient characteristics, intraoperative details, postoperative outcomes, and infection details were assessed.
Impact of polypharmacy on patients undergoing revascularisation for peripheral arterial disease.
Vasa
January 2025
Department of Vascular Surgery, Ludwig-Maximillians-University Hospital Munich, Germany.
To evaluate the impact of polypharmacy, defined as the concurrent use of five or more medications, on the clinical outcomes of patients undergoing revascularisation for symptomatic peripheral arterial disease (PAD). This is a retrospective analysis of consecutive PAD patients treated by surgical, endovascular or hybrid therapy in a tertiary center between January 2017 and December 2017. The composite of amputation and/or death (amputation-free survival; AFS) was the primary endpoint.
View Article and Find Full Text PDFClinical Outcomes following Invasive Treatment of Femoropopliteal Artery Disease: A Retrospective Single-Center Cohort Study.
J Vasc Interv Radiol
January 2025
Department of Surgery, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Article Synopsis
- The study aimed to identify factors that predict clinical success in invasive treatments for femoropopliteal disease to help guide medical decisions.
- A retrospective analysis was conducted on 676 patients who received either endovascular therapy (EVT) or femoropopliteal bypass (FPB), with key outcomes including clinical patency and amputation rates.
- Critical limb-threatening ischemia (CLTI) was found to negatively impact primary clinical patency, while factors like FPB surgery, higher ankle-brachial index, and more distal runoff vessels positively influenced secondary clinical patency.
Technical aspects of the new BYCROSS atherectomy device - preliminary results after 28 patients.
Vasa
November 2024
Vascular Surgery, Medical Faculty, University of Augsburg, Germany.
Unlabelled: Purpose: Technical aspects are crucial for the planning and performing of the atherectomy to treat peripheral arterial disease. This report illustrates the use of a novel atherectomy device and investigates the feasibility, efficacy, and safety procedures involved in performing the atherectomy on 28 patients.
Materials And Methods: We performed a prospective analysis of patients who underwent an atherectomy with the BYCROSS Atherectomy device between August 2022 and September 2023 at a tertiary referral centre.
Association between Regional Market Competition and Early Femoropopliteal Interventions for Claudication.
Ann Vasc Surg
January 2025
Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, The Johns Hopkins School of Medicine, Baltimore, MD. Electronic address:
Background: Regional market competition is known to impact practice patterns in surgical care. We aimed to investigate the association of regional market competition with the utilization of early peripheral vascular interventions (PVIs) for the treatment of claudication, and the subsequent impact on clinical outcomes.
Methods: We conducted a retrospective analysis of 100% Medicare fee-for-service claims data from January 2019 to December 2021 to identify patients with a new diagnosis of claudication.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!